Cold Email Outreach to Neurology Practice Owner in HealthcareCold Email Outreach to Neurology Practice Owner in Healthcare

AAN membership directory and state medical board licensure databases identify neurologists by name, subspecialty, and practice address. Cross-reference with the practice's LLC or corporate filing to confirm ownership. Hospital employment is the highest of any subspecialty (60%+) — verify independent ownership using CMS PECOS data and business filings. This will eliminate the majority of neurologists from independent practice targeting. The independent market is estimated at ~6,000-7,000 neurologists. AANEM membership identifies neurologists with electrodiagnostic capabilities. Practices with infusion programs or subspecialty center designations are more likely to be independently owned. Skyp's data cross-references AAN, AANEM, NPI, CMS, state board, and business entity records.

Biologic infusion is transforming neurology practice economics across multiple subspecialties. Migraine: Vyepti (eptinezumab) is the only infused CGRP inhibitor, administered quarterly with infusion revenue of $2,000-3,000+ per patient per year. MS: Ocrevus (ocrelizumab) is the dominant infused MS biologic, administered every 6 months at $30,000+/year with significant buy-and-bill margin. Alzheimer's: Leqembi (lecanemab) and Kisunla (donanemab) require biweekly or monthly infusions with ARIA monitoring, generating substantial per-patient revenue but requiring MRI monitoring infrastructure. Practices that build infusion programs across these indications can see infusion revenue grow to 30-50%+ of total practice revenue. The infrastructure investment (infusion chairs, nursing staff, drug inventory) pays back rapidly at scale.

EMG/NCS and EEG volume per neurologist (the neurodiagnostic revenue metric), infusion program revenue and biologic patient volume, new patient wait time (the access metric), patients per neurologist per day, revenue per patient encounter (including diagnostics and infusion), APP leverage ratio (NPs/PAs extending neurologist capacity), and subspecialty-specific volumes (migraine patients on CGRP therapy, MS patients on disease-modifying therapy). Practices with infusion programs track chair utilization and per-infusion revenue. AAN practice surveys and neurology-specific consultants provide the benchmarks they reference.

In-office neurodiagnostic testing is a significant revenue driver for neurology practices. EMG/nerve conduction studies ($300-800+ per study) are performed by neurologists with electrodiagnostic training — practices that perform EMG in-office capture this revenue rather than referring to hospital labs. EEG ($200-500+ per routine study, more for ambulatory or video EEG) provides diagnostic revenue for epilepsy and other conditions. Practices with neurodiagnostic labs generate 20-35% higher per-patient revenue than those referring diagnostics out. However, not all neurologists perform EMG/NCS (requires specific AANEM training), and EEG requires technologist staffing and equipment investment. Solutions that improve neurodiagnostic scheduling, workflow, or billing efficiency address an important ancillary revenue lever.

Slower than most — typically within 4-7 business days. Neurologists are among the most time-constrained specialists (complex patients, long visits, high administrative burden from prior authorizations for biologics and diagnostics). However, they're responsive to subspecialty-specific emails that address infusion program development, neurodiagnostic optimization, or capacity management. The high hospital employment rate means the independent audience is smaller but more engaged with practice operations. Skyp's neurology sequences use 5-6 day intervals, segment by subspecialty and infusion/diagnostic capability, and target early morning or post-clinic sends.